Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L- glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5427-5437

  Baek, Sora ^a   Choi, Chang Min ^a   Ahn, SeiHyun ^a   Lee, JongWon ^a   Gong, Gyungyub ^a   Ryu, Jin Sook ^a   Oh, SeungJun ^a   Bacher Stier, Claudia ^b   Fels, Lüder ^b   Koglin, Norman ^b   Hultsch, Christina ^b   Schatz, Christoph A ^b   Dinkelborg, Ludger M ^c   Mittra, Erik S ^d   Gambhir, Sanjiv S ^d,e   Moon, Dae Hyuk ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b BAYER PHARMA AG   (Germany)

^c Piramal Enterprises Limited   (India)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 94 9392; CARRIER PROTEIN; CD44 ANTIBODY; FLORILGLUTAMIC ACID F 18; FLUORODEOXYGLUCOSE F 18; HERMES ANTIGEN; HORMONE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; XC TRANSPORTER;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; EXPLORATORY RESEARCH; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE ABSORPTION; LUNG NON SMALL CELL CANCER; MALE; MASTECTOMY; OPEN STUDY; PANCREAS; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RADIATION EXPOSURE; SINGLE DRUG DOSE; STANDARDIZED UPTAKE VALUE;

ADULT; AGED; AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CONTRAST MEDIA; FEMALE; GLUTAMATES; HUMANS; MICE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

EID: 84866926512     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0214     Document Type: Article

References (34)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
3. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010;330:1340-4.
4. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010;29:313-24.
5. Mankoff DA, Eary JF, Link JM, Muzi M, Rajendran JG, Spence AM, et al. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res 2007;13:3460-9. (Pubitemid 46955105)
6. Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 2006;43:143-81. (Pubitemid 43860449)
7. Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 1999;274:11455-8.
8. Banjac A, Perisic T, Sato H, Seiler A, Bannai S, Weiss N, et al. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. Oncogene 2008;27:1618-28. (Pubitemid 351347880)
9. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007;67:9463-71. (Pubitemid 47535936)
10. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 2005;65:7446-54. (Pubitemid 41161279)
11. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45. (Pubitemid 36077255)
12. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;11:254-67.
13. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400.
14. Koglin N, Mueller A, Berndt M, Schmitt-Willich H, Toschi L, Stephens AW, et al. Specific PET imaging of xC- transporter activity using a(1)F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res 2011;17:6000-11.
15. Yoon DH, Baek S, Choi CM, Lee DH, Suh C, Ryu JS, et al. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy. Clin Cancer Res 2011;17:5093-100.
16. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
17. Liu R, Blower PE, Pham AN, Fang J, Dai Z, Wise C, et al. Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Mol Pharmacol 2007;72:1637-46. (Pubitemid 350146101)
18. Bassi MT, Gasol E, Manzoni M, Pineda M, Riboni M, Martin R, et al. Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system xc. P flugers Arch 2001;442:286-96. (Pubitemid 32476650)
19. Burdo J, Dargusch R, Schubert D. Distribution of the cystine/glutamate antiporter system xc- in the brain, kidney, and duodenum. J Histochem Cytochem 2006;54:549-57.
20. Chintala S, Li W, Lamoreux ML, Ito S, Wakamatsu K, Sviderskaya EV, et al. Slc7a11 gene controls production of pheomelanin pigment and proliferation of cultured cells. Proc Natl Acad Sci U S A 2005;102:10964-9. (Pubitemid 41105976)
21. Kandil S, Brennan L, McBean GJ. Glutathione depletion causes a JNK and p38MAPK-mediated increase in expression of cystathionine-gamma-lyase and upregulation of the transsulfuration pathway in C6 glioma cells. Neurochem Int 2010;56:611-9.
22. Zhang W, Braun A, Bauman Z, Olteanu H, Madzelan P, Banerjee R. Expression profiling of homocysteine junction enzymes in the NCI60 panel of human cancer cell lines. Cancer Res 2005;65:1554-60. (Pubitemid 40270185)
23. Hanigan MH. Expression of gamma-glutamyl transpeptidase provides tumor cells with a selective growth advantage at physiologic concentrations of cyst(e)ine. Carcinogenesis 1995;16:181-5.
24. Hanigan MH, Frierson HF Jr, Swanson PE, De Young BR. Altered expression of gamma-glutamyl transpeptidase in human tumors. Hum Pathol 1999;30:300-5. (Pubitemid 29125150)
25. Hochwald SN, Harrison LE, Rose DM, Anderson M, Burt ME. Gamma-glutamyl transpeptidase mediation of tumor glutathione utilization in vivo. J Natl Cancer Inst 1996;88:193-7.
26. Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A 2002;99:1491-6. (Pubitemid 34136520)
27. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol 2012;14:276-86.
28. Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 2004;53:567-79. (Pubitemid 38858330)
29. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519-27. (Pubitemid 47618506)
30. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
31. Bannai S. Exchange of cystine and glutamate across plasma membrane of human fi broblasts. J Biol Chem 1986;261:2256-63. (Pubitemid 17205155)
32. Tsai PJ, Huang PC. Circadian variations in plasma and erythrocyte concentrations of glutamate, glutamine, and alanine in men on a diet without and with added monosodium glutamate. Metabolism 1999;48:1455-60.
33. Park Y, Ziegler TR, Gletsu-Miller N, Liang Y, Yu T, Accardi CJ, et al. Postprandial cysteine/cystine redox potential in human plasma varies with meal content of sulfur amino acids. J Nutr 2010;140:760-5.
34. Stegink LD, Filer LJ Jr., Baker GL. Plasma glutamate concentrations in adult subjects ingesting monosodium L-glutamate in consomme. Am J Clin Nutr 1985;42:220-5. (Pubitemid 16246352)